Minerva Neurosciences (NERV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Apr, 2026Executive summary
The annual meeting will be held virtually on June 3, 2026, with stockholders able to participate and vote online.
Six key proposals are up for vote, including director elections, charter amendments, executive compensation, and auditor ratification.
Only stockholders of record as of April 9, 2026, are entitled to vote, with detailed procedures for proxy and online voting.
Voting matters and shareholder proposals
Election of two Class III directors to serve until 2029.
Amendment to the certificate of incorporation to allow officer exculpation under Delaware law.
Amendment to eliminate the exclusive forum provision from the charter.
Advisory vote on executive compensation (say-on-pay) and on the frequency of future say-on-pay votes, with the board recommending annual votes.
Ratification of Deloitte & Touche LLP as independent auditor for 2026.
Board of directors and corporate governance
Board consists of six members divided into three classes, with biographies and qualifications provided for each.
Majority of directors are independent per Nasdaq standards; CEO serves as board chair, with a lead independent director appointed.
Three standing committees: Audit, Compensation, and Nominating and Corporate Governance, all with independent members.
Stockholders can communicate directly with the board and recommend director candidates.
Code of Ethics applies to all officers, directors, and employees.
Latest events from Minerva Neurosciences
- Q2 2026 net income was $17.5M, but a six-month net loss of $107.9M highlights funding needs.NERV
Q2 2026 - Roluperidone targets negative symptoms in schizophrenia, with pivotal data expected in 2027.NERV
Jefferies Global Healthcare Conference 2026 - All proposals, including director elections and governance amendments, were approved.NERV
AGM 2026 - Roluperidone advances as the first late-stage therapy for negative symptoms of schizophrenia.NERV
Corporate presentation - Net loss rose to $125.4M on non-cash warrant expenses as Phase 3 roluperidone trial launched.NERV
Q1 2026 - Roluperidone shows promise for negative symptoms in schizophrenia, with pivotal trial results due next year.NERV
Stifel 2026 Virtual CNS Forum - Key votes include director elections, charter changes, and auditor ratification for 2026.NERV
Proxy filing - Six key proposals, including director elections and charter amendments, headline the 2026 annual meeting.NERV
Proxy filing - Registering up to $200M in securities to fund CNS drug development and corporate growth.NERV
Registration Filing